What's trending

5 most popular innovation stories in Houston this week

Medical professionals weigh in on the future of health care, top Houston research news, and more stories that trended this week on InnovationMap. Photo via Getty Images

Editor's note:Another week has come and gone, and it's time to round up the top headlines from the past few days. Trending Houston tech and startup news on InnovationMap included innovators to know, a guest column responding to Winter Storm Uri, health care professionals overheard at a panel on COVID-19, and more.


4 female Houston innovators to know this week

This week's roundup of Houston innovators includes Dorit Donoviel of TRISH, Anu Pansare of gBETA, and Christine Galib and Courtney Cogdill of The Ion. Courtesy photos

In the week's roundup of Houston innovators to know, I'm introducing you to four innovators across industries recently making headlines — from space tech to startup development organizations. Continue reading.

Unleashing innovation for resilience is more urgent than ever, says Houston expert

Looking back on the past few days of low temperatures, ice, snow, power and water outages, and more, it's time to focus on innovation for resilience. Photo courtesy of ABC13

Greater Houston and all of Texas have faced enough persistent challenges over the past seven years that communities and businesses are at a breaking point. Not just financially and economically, but at societal and emotional levels expected from repeated natural and man-made disasters.

Increasingly, the focus on "resilience" as a call to action has become a buzzword rather than measure of performance by public and private sector decision-makers. Simply, our version of resilience is defined as pre-disaster risk mitigation and investment, not recovery and rebuilding after the fact, which is precisely what is being debated across traditional and social media.

As families, small businesses, larger corporations, neighborhoods, and communities require stability, predictability, and frankly reliability, there is now disappointment and disillusion across party lines for our public agencies, programs, officials. When the last major freeze and snowfall hit Texas, the state's power grid ERCOT and the legislature were warned that unless immediate steps were taken to invest in our electrical grid, an expected collapse of the entire system would leave entire cities and potentially the state in darkness with life-threatening consequences. Review any of the published recommendations from previous disasters and each conclusion identifies necessary and urgent investment, re-engineering, and technological innovation. And yet many of those findings are but another can kicked down the road. Continue reading.

Tech company to grant funds to Houston-area BIPOC small business owners

Comcast is looking out for the one-third of businesses in the Houston metro area that are minority-owned. Photo courtesy of comcast.

Comcast, the telecom, media, and entertainment conglomerate, is awarding $1 million in grants to small businesses in Houston owned by entrepreneurs who are Black, indigenous or people of color (BIPOC).

In all, 100 grants of $10,000 each will be given to BIPOC-owned small businesses in Houston. Local businesses can apply for the grants March 1-14. Grant recipients will be announced in April and awarded in May. Continue reading.

Overheard: Houston health care experts sound off on how tech and COVID-19 have affected the industry

Health care leaders joined a virtual panel to discuss the effects of COVID-19 and more. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

There has been an undeniable paradigm shift in the health care industry due to COVID-19 as well as the growth of technology. A group of professionals sat down to discuss what in particular has changed for the industry as a whole as well as at local institutions.

At a panel for Venture Houston, a two-day conference put on by the HX Venture Fund on February 4th and 5th, a few health care professionals weighed in on all the changes to the industry for the startups, investors, corporations, and more who attended the virtual event. Here are some significant overheard moments from the virtual panel — Thinking Past a COVID World. Continue reading.

These 3 Houston researchers are revolutionizing health science innovation

From biomolecular research to oral cancer immunotherapy, here are three researchers to watch out for in Houston. Photo via Getty Images

Research, perhaps now more than ever, is crucial to expanding and growing innovation in Houston — and it's happening across the city right under our noses.

In InnovationMap's latest roundup of research news, a couple local scientists are honored by awards while another duo of specialists tackle a new project. Continue reading.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted